Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases

J Allergy Clin Immunol. 2017 Sep;140(3):685-687. doi: 10.1016/j.jaci.2017.04.029. Epub 2017 May 12.

Authors

Dhavalkumar D Patel¹, Christian Antoni², Steven J Freedman³, Marc C Levesque⁴, John S Sundy⁵

Affiliations

¹ Novartis, Basel, Switzerland. Electronic address: dhavalkumar.d.patel@gmail.com.
² Sanofi, Bridgewater, NJ.
³ MedImmune, Gaithersburg, Md.
⁴ AbbVie, Boston, Mass.
⁵ Gilead Sciences, Foster City, Calif.

PMID: 28506849
DOI: 10.1016/j.jaci.2017.04.029

No abstract available

Keywords: Drug development; biomarker; clinical trials; pharmacodynamics; trial design.

Publication types

Editorial

MeSH terms

Clinical Trials, Phase II as Topic*
Clinical Trials, Phase III as Topic*
Drug Development*
Humans
Immune System Diseases / drug therapy*
Research Design